Antares Pharma — Investor Presentation (August 2017)
20 slides from Antares Pharma's investor presentation, Aug 9, 2017
Slide 1: Antares Pharma August 2017
NASDAQ: ATRS August 2017 Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement 2 This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ ma
Slide 3: Antares Pharma: A Growing, Revenue Generating Specialty Pharmaceutical Company
Antares Pharma A Growing, Revenue Generating State-of-the-Art Specialty Pharmaceutical Company An Innovative Leader in Self-Administered Injection Technology Two combination products approved and on the U.S. market (OTREXUP®, Sumatriptan) and one combination product approved in Europe with marketing
Slide 4: XYOSTED Launch Plan
XYOSTED™ Launch Plan AYOSTED (testosterone enanthate) injection @
Slide 5: Commercial Launch Planning Underway
Commercial Launch Planning Underway! PDUFA Date: October 20, 2017 Key Next Steps: Finalization of WAC price Finalization of Payer Access Strategy and Prioritization Finalization of all Marketing Assets and Activities Distribution Strategy and Trade Negotiations Sales Representative recruitment (pend
Slide 6: Commercial Launch Plan
Commercial Launch Plan Territory alignment and mapping complete 7 Regional Sales Managers (RSM) and 60 Specialty Account Representatives (SAR) RSM start date ~ August 1 Sales training tools in development SAR anticipated start date ~ December 1 (assuming FDA approval)
Slide 7: Managed Markets Research
Managed Markets Research Payer advisory board held in conjunction with Academy of Managed Care Pharmacy meeting in April Conducted in-depth payer research to clarify areas of interest surrounding launch of XYOSTED Goal of the advisory board and payer research: To better understand coverage and manag
Slide 8: XYOSTED Product Profile
Name XYOSTED™ - Subcutaneous Testosterone Enanthate in an auto injector Dosing Once weekly, single use, fixed dose subcutaneous product Doses 50 mg/0.5 mL TE in solution 75 mg/0.5 mL TE in solution 100 mg/0.5 mL TE in solution Product Features Easy to use and store at room temperature Auto injector
Slide 9: Testosterone Replacement Market: 2015-17 Retail Prescriptions
Testosterone Replacement Market: 2015-17 Retail Prescriptions Symphony Health Solutions: Phast IDV 2016 2015
Slide 10: VIBEX Sumatriptan Auto Injector
VIBEX® Sumatriptan Auto Injector Q217 product revenue of $2.3 million generated from the shipment of sumatriptan to Teva - $15 million since launch (Q216 – Q217) Market Share week ended 7/21 = 29%* VIBEX® Sumatriptan Injection USP *Symphony Health Solutions Weekly TRx Data
Slide 11: OTREXUP Quarterly Revenue/TRx Progression
OTREXUP® Quarterly Revenue/TRx* Progression *Total Quarterly Prescriptions Per Symphony Health Solutions/Bloomberg Intelligence OTREXUP® TRx Data OTREXUP® Revenue Q114 Q214 Q314 Q414 Q115 Q215 Q315 Q415 Q116 Q216 Q316 Q416 Q117 Q217 10,770 $3.9 M
Slide 12: Generic Byetta (exenatide) Multi-Dose Pen
Generic Byetta® (exenatide) Multi-Dose Pen Teva announced settlement with AstraZeneca and Amylin which allows Teva to launch on October 15, 2017, pending FDA approval Teva filed ANDA in December 2014 and it is under FDA review – Antares believes Teva has first to file status and 180 days of marketin
Slide 13: VIBEX Epinephrine
VIBEX® Epinephrine Teva filed ANDA amendment with FDA in December 2014, Complete Response Letter (CRL) issued February 2016, Teva submitted responses to CRL in Q117 and they are targeting a launch in early 2018 Shipped ~$20 million worth of devices to date Agreement with Teva – ATRS will receive mar
Slide 14: Generic Forteo (teriparatide) Multi-Dose Pen
Generic Forteo® (teriparatide) Multi-Dose Pen Teva ANDA accepted by FDA 2/16; Lilly filed a lawsuit in response to Teva’s Paragraph IV notice, 30 month stay expires in August 2018. Lilly has agreed not to sue Teva on the device patent (which expires in 2025) - last to expire orange book patent is no
Slide 15: Makena
Makena® AMAG/Makena® alliance began in 2014 Antares is using the QuickShot device to develop a once-weekly subcutaneous injection of Makena Potentially better patient compliance Potentially easier administration Currently administered IM with a large-gauge needle from a single dose vial, Auto-inject
Slide 16: Second Quarter and Year-to-Date 2017 Revenue Mix
Second Quarter and Year-to-Date 2017 Revenue Mix Three Months Ended June 30 Increase Six Months Ended June 30 Increase 2017 2016 (Decrease) 2017 2016 (Decrease) OTREXUP $3,923 $3,810 3% $ 8,487 $7,120 19% Auto injector and pen injector devices 2,435 3,914 (38%) 6,544 9,892 (34%) Needle-free injector
Slide 17: Second Quarter and Year-to-Date 2017 Financial Results
Second Quarter and Year-to-Date 2017 Financial Results Three Months Ended June 30 Increase Six Months Ended June 30 Increase 2017 2016 (Decrease) 2017 2016 (Decrease) Total Revenue $ 13,416 $ 12,228 10% $ 25,424 $ 24,547 4% Cost of Revenue 5,616 7,318 (23%) 11,836 14,094 (16%) Gross Profit 7,800 4,9
Slide 18: Debt Financing From Hercules Capital
Debt Financing From Hercules Capital Five year term loan agreement provides up to $35 million First tranche of $25 million was funded upon execution of the loan agreement Antares has an option to draw up to an additional $10 million upon achievement of a certain milestone Payments under the loan are
Slide 19: ATRS Investment Considerations
ATRS Investment Considerations A revenue generating Specialty Pharmaceutical Company poised for growth Ongoing Catalysts: XYOSTED™ NDA under active review at FDA – October 20, 2017 PDUFA date Sumatriptan Injection USP launched – TRx share ~29% per weekly TRx data (7/21/17) Continued TRx Growth of OT
Slide 20: Making medicines better
making medicines better he antares pharma August 2017